Do we need new treatments for type 2 diabetes?

被引:0
|
作者
Gomez-Peralta, Fernando [1 ]
Abreu Padin, Cristina [1 ]
机构
[1] Hosp Gen Segovia, Unidad Endocrinol & Nutr, Segovia, Spain
来源
ENDOCRINOLOGIA Y NUTRICION | 2014年 / 61卷 / 06期
关键词
Diabetes; Future treatment; Antidiabetic drugs; Hypoglycemia; Weight;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diagnosis of type 2 diabetes mellitus encompasses multiple pathophysiological and clinical situations. Type 2 diabetes mellitus is characterized by a long and changing natural history. Personal circumstances and preferences also condition the actual effectiveness and safety of drugs used. In recent decades, modern drugs have markedly expanded and improved therapeutic options. However, their effectiveness remains limited in clinical practice. The main objective of decreasing macrovascular complications is not fully proven. Adverse events, especially hypoglycemia and weight gain, are still frequent and decrease treatment adherence. The constant loss of endogenous islet cell reserve is the main determinant of the need for intensified therapies. Current treatments have failed to improve long-term beta cell mass/function. It is desirable to move forward to obtain new drugs that offer solutions sustainable in the long term. These drugs should be able to fit the individual circumstances and preferences of patients with diabetes mellitus. (C) 2013 SEEN. Published by Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码:323 / 328
页数:6
相关论文
共 50 条
  • [31] Finerenone: Do We Really Need an Additional Therapy in Type 2 Diabetes Mellitus and Kidney Disease?
    Manoharan, Deepika
    Gangoo, Nicholas
    Hinchliffe, William
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2025, 86 (01)
  • [32] When People with Type-1 Diabetes become adults Diabetes Technology and Transition - do we need new Models?
    Datz, Nicolin
    Kordonouri, Olga
    Danne, Thomas
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2021, 146 (18) : 1200 - 1205
  • [33] Exocrine pancreatic insufficiency in type 1 and type 2 diabetes mellitus: do we need to treat it? A systematic review
    Zsori, Gabor
    Illes, Dora
    Terzin, Viktoria
    Ivany, Emese
    Czako, Laszlo
    PANCREATOLOGY, 2018, 18 (05) : 559 - 565
  • [34] Primary prevention of type 2 diabetes: How do we do it?
    Abdul-Ghani, MA
    Sabah, M
    Minuchin, O
    Vardi, P
    Raz, I
    Wainstein, J
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2004, 6 (05): : 305 - 307
  • [36] NEW TECHNOLOGY - DO WE NEED IT
    MAY, JR
    CIM BULLETIN, 1984, 77 (870): : 52 - 52
  • [37] Do we need a new levodopa?
    Mueller, Thomas
    NEURAL REGENERATION RESEARCH, 2016, 11 (05) : 731 - 732
  • [38] Do we need new antidepressants?
    Hindmarch, I
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 1997, 12 : S115 - S119
  • [39] Do we need new guidelines?
    Jaeger, K. A.
    ULTRASCHALL IN DER MEDIZIN, 2008, 29 (01): : 24 - 27
  • [40] Do all patients with type 2 diabetes need breakfast?
    Parkner, T.
    Nielsen, J. K.
    Sandahl, T. D.
    Bibby, B. M.
    Jensen, B. S.
    Christiansen, J. S.
    EUROPEAN JOURNAL OF CLINICAL NUTRITION, 2011, 65 (06) : 761 - 763